PROS1 and COVID-19: We and others have developed several COVID-19 vaccine candidates based on the poxvirus-modified vaccinia virus Ankara (MVA) vector expressing the S protein that have shown a potent immunogenicity profile and full efficacy in several animal models, such as mice (15–21), hamsters (22), and non-human primates (NHPs) (20).